COVID-19 vaccine effectiveness against the omicron (BA. 2) variant in England

FCM Kirsebom, N Andrews, J Stowe, S Toffa… - The Lancet Infectious …, 2022 - thelancet.com
The omicron (B. 1.1. 529) variant, first detected in the UK on Nov 27, 2021, rapidly became
the dominant strain, due in part to reduced vaccine effectiveness. 1 An increase in …

Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA. 4 and BA. 5 in England

FCM Kirsebom, N Andrews, J Stowe… - The Lancet Regional …, 2022 - thelancet.com
The Omicron sub-lineages BA. 4 and BA. 5, identified in South Africa in early 2022, 1 were
first detected in England in April 2022. 2 A case surge followed despite England having …

BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA. 4 and BA. 5

SY Tartof, JM Slezak, L Puzniak, V Hong… - The Lancet Infectious …, 2022 - thelancet.com
Correspondence 1664 www. thelancet. com/infection Vol 22 December 2022 emergency
department encounters only in the first 3 months after a third dose of vaccine (table). At 6 …

Effectiveness of BNT162b2 against COVID-19 in adolescents

AA Powell, F Kirsebom, J Stowe, K McOwat… - The Lancet Infectious …, 2022 - thelancet.com
In the UK, COVID-19 vaccination for adults began in December, 2020. 1 Because children
and adolescents have a low risk of severe COVID-19 and due to concerns about rare but …

Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant

N Andrews, J Stowe, F Kirsebom, S Toffa… - … England Journal of …, 2022 - Mass Medical Soc
Background A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the
omicron (B. 1.1. 529) variant of severe acute respiratory syndrome coronavirus 2 in highly …

Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA. 1 boosters against COVID-19 hospitalisation in England: a test …

FCM Kirsebom, N Andrews, J Stowe… - The Lancet Infectious …, 2023 - thelancet.com
Background Bivalent BA. 1 booster vaccines were offered to adults aged 50 years or older
and clinically vulnerable people as part of the 2022 autumn COVID-19 booster vaccination …

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA. 1, BA. 2, and BA. 3

P Arora, L Zhang, C Rocha, A Sidarovich… - The Lancet Infectious …, 2022 - thelancet.com
The SARS-CoV-2 omicron (B. 1.1. 529) variant has rapidly become globally dominant,
displacing the previously dominant delta (B1. 617.2) variant. The viral spike (S) protein is the …

Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern

N Andrews, J Stowe, F Kirsebom, S Toffa, T Rickeard… - MedRxiv, 2021 - medrxiv.org
Background A rapid increase in cases due to the SARS-CoV-2 Omicron (B. 1.1. 529) variant
in highly vaccinated populations has raised concerns about the effectiveness of current …

Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England

N Andrews, J Stowe, F Kirsebom, S Toffa… - Nature medicine, 2022 - nature.com
Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in
England starting on 14 September 2021. We used a test-negative case–control design to …

Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting

O Magen, JG Waxman, M Makov-Assif… - … England Journal of …, 2022 - Mass Medical Soc
Background With large waves of infection driven by the B. 1.1. 529 (omicron) variant of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alongside evidence of …